- Home
- LXEH vs VINC Comparison
LXEH vs VINC Comparison
Compare LXEH & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- VINC
- Stock Information
- Founded
- LXEH 2001
- VINC 2019
- Country
- LXEH China
- VINC United States
- Employees
- LXEH N/A
- VINC N/A
- Industry
- LXEH Other Consumer Services
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- VINC Health Care
- Exchange
- LXEH Nasdaq
- VINC Nasdaq
- Market Cap
- LXEH 5.7M
- VINC 6.2M
- IPO Year
- LXEH 2020
- VINC N/A
- Fundamental
- Price
- LXEH $4.92
- VINC $0.15
- Analyst Decision
- LXEH
- VINC Buy
- Analyst Count
- LXEH 0
- VINC 2
- Target Price
- LXEH N/A
- VINC $2.00
- AVG Volume (30 Days)
- LXEH 105.0K
- VINC 21.3M
- Earning Date
- LXEH 03-15-2025
- VINC 11-12-2024
- Dividend Yield
- LXEH N/A
- VINC N/A
- EPS Growth
- LXEH N/A
- VINC N/A
- EPS
- LXEH N/A
- VINC N/A
- Revenue
- LXEH $5,628,870.00
- VINC N/A
- Revenue This Year
- LXEH N/A
- VINC N/A
- Revenue Next Year
- LXEH N/A
- VINC N/A
- P/E Ratio
- LXEH N/A
- VINC N/A
- Revenue Growth
- LXEH N/A
- VINC N/A
- 52 Week Low
- LXEH $1.95
- VINC $0.14
- 52 Week High
- LXEH $65.06
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- LXEH 53.73
- VINC 37.12
- Support Level
- LXEH $4.70
- VINC $0.14
- Resistance Level
- LXEH $5.45
- VINC $0.52
- Average True Range (ATR)
- LXEH 0.51
- VINC 0.04
- MACD
- LXEH -0.14
- VINC -0.00
- Stochastic Oscillator
- LXEH 26.64
- VINC 3.25
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.